Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.

[1]  M. L. Specchia,et al.  The impact of tumor board on cancer care: evidence from an umbrella review , 2020, BMC Health Services Research.

[2]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[3]  J. Marcickiewicz,et al.  Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. , 2019, Gynecologic oncology.

[4]  C. Schade-Brittinger,et al.  TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7) , 2019, International Journal of Gynecological Cancer.

[5]  J. Marcickiewicz,et al.  Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer – a Swedish Gynecologic Cancer Group (SweGCG) study , 2019, Acta oncologica.

[6]  H. Seale,et al.  Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation , 2019, BMC Public Health.

[7]  M. Parmar,et al.  Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. , 2018, The Lancet. Oncology.

[8]  P. Kjølhede,et al.  Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease – a Swedish Gynecologic Cancer Group (SweGCG) study , 2017, Acta oncologica.

[9]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  I. Vergote,et al.  European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery , 2017, International Journal of Gynecologic Cancer.

[11]  P. Kjølhede,et al.  Data quality in the Swedish Quality Register of Gynecologic Cancer – a Swedish Gynecologic Cancer Group (SweGCG) study , 2017, Acta oncologica.

[12]  P. Kjølhede,et al.  Risk factors for lymph node metastases in women with endometrial cancer: A population‐based, nation‐wide register study—On behalf of the Swedish Gynecological Cancer Group , 2017, International journal of cancer.

[13]  P. Dahm-Kähler,et al.  Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. , 2016, Gynecologic oncology.

[14]  W. van Driel,et al.  Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands. , 2016, Gynecologic oncology.

[15]  G. Rustin,et al.  Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities , 2016, Archives of Gynecology and Obstetrics.

[16]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[17]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[18]  Jenny Chang,et al.  Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. , 2013, Gynecologic oncology.

[19]  S. Kehoe,et al.  Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. , 2012, The Cochrane database of systematic reviews.

[20]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[21]  M. Castiglione,et al.  Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[23]  M. van der Aa,et al.  Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. , 2018, Gynecologic oncology.

[24]  E. Åvall-Lundqvist,et al.  Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). , 2017, Gynecologic oncology.

[25]  J. Dungan,et al.  Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer , 2011 .